SCA
GILD icon

STALEY CAPITAL ADVISERS’s Gilead Sciences GILD Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,000
Closed -$245K – 192
2025
Q4 		$245K Hold
2,000
– – 0.01% 169
2025
Q3 		$222K Buy
+2,000
New +$227K 0.01% 179

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

STALEY CAPITAL ADVISERS's GILD Position: Q1 2026 in Review

STALEY CAPITAL ADVISERS sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 2,000 shares — an estimated $245K sold.

STALEY CAPITAL ADVISERS first reported a position in GILD in Q3 2025 and held it in 2 quarters. The position peaked at $245K in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • STALEY CAPITAL ADVISERS reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • STALEY CAPITAL ADVISERS sold 2,000 Gilead Sciences shares in Q1 2026, an estimated $245K.
  • STALEY CAPITAL ADVISERS first reported a position in Gilead Sciences in Q3 2025 and held it in 2 quarters.
  • STALEY CAPITAL ADVISERS's Gilead Sciences position peaked at $245K in Q4 2025.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q1 2026, filed 29 Apr 2026.